Sökning: "aggressive lymphoma"
Visar resultat 1 - 5 av 37 avhandlingar innehållade orden aggressive lymphoma.
1. Aggressive lymphoma
Sammanfattning : Aggressive lymphoma is a rapidly growing tumour of lymphocyte origin, potentially curable with chemotherapy. In a trial by the Nordic Lymphoma Group, 405 patients with aggressive lymphoma were included, and randomised to receive either the standard chemotherapy regimen, CHOP, or a weekly multidrug regimen, MACOP-B. LÄS MER
2. Hodgkin Lymphoma : Studies of Advanced Stages, Relapses and the Relation to Non-Hodgkin Lymphomas
Sammanfattning : The relationship between Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) is not entirely elucidated and a clonal relation may be present more often than previously believed. Mechanisms of tumour progression and resistance to therapy are poorly understood.Between 1974 and 1994 all individuals in Sweden with both HL and NHL were identified. LÄS MER
3. Genetic Alterations in Lymphoma : with Focus on the Ikaros, NOTCH1 and BCL11B Genes
Sammanfattning : Cell proliferation is a process that is strictly regulated by a large number of proteins. An alteration in one of the encoding genes inserts an error into the regulative protein, which may result in uncontrolled cell growth and eventually tumor formation. LÄS MER
4. Protein kinases and phosphatases in B-cell lymphoma
Sammanfattning : Around 2000 persons are diagnosed with lymphoma in Sweden each year. There are many subgroups described for this form of cancer and the great majority is derived from B-cells. The most common subgroup is Diffuse large B-cell lymphoma (DLBCL), a highly aggressive disease where only half of the patients are cured. LÄS MER
5. Burkitt lymphoma and diffuse large B-cell lymphoma – therapeutic strategies and pathogenetic mechanisms
Sammanfattning : Burkitt lymphoma (BL) is a rare, aggressive disorder constituting 1% of all non-Hodgkin lymphoma. Diffuse large B-cell lymphoma (DLBCL) is more common, accounting for 30% of malignant lymphoma. Standard treatment for adult BL and for certain subgroups of patients with DLBCL remains to be defined due to paucity of randomised trials performed. LÄS MER